These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12480299)

  • 1. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL; Walton K; Slob W; Renwick AG
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):201-24. PubMed ID: 12480298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
    Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
    Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
    Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
    Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
    Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
    J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.
    Jiang ZP; Shu Y; Chen XP; Huang SL; Zhu RH; Wang W; He N; Zhou HH
    Eur J Clin Pharmacol; 2002 May; 58(2):109-13. PubMed ID: 12012142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
    Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J
    Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
    Liu ZQ; Cheng ZN; Huang SL; Chen XP; Ou-Yang DS; Jiang CH; Zhou HH
    Br J Clin Pharmacol; 2001 Jul; 52(1):96-9. PubMed ID: 11453896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.